Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,104,757 shares
Latest Disclosed Value $ 21,211,369
Morgan Stanley reports 9.44% decrease in ownership of DNLI / Denali Therapeutics Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,104,757 shares of Denali Therapeutics Inc. (US:DNLI) valued at $21,211,334 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,219,854 shares of Denali Therapeutics Inc.. This represents a change in shares of -9.44% during the quarter. The current value of the position is $22,249,806 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,104,757 -115,097 -9.44 21,211 5.32 0.0013
2026-05-27 2025-12-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,219,854 -469,638 -27.80 20,140 -17.90 0.0012
2026-02-13 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,219,854 -469,638 20,140 0.0012
2026-05-27 2025-09-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,689,492 377,476 28.77 24,531 33.65 0.0015
2025-11-14 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,689,492 377,476 24,531 0.0015
2025-08-15 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,312,016 58,413 4.66 18,355 7.70 0.0012
2025-05-15 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,253,603 24,463 1.99 17,043 -31.97 0.0012
2025-05-15 2024-12-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,229,140 -515,615 -29.55 25,050 -50.71 0.0018
2025-02-14 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,229,140 -515,615 25,050 0.0018
2025-05-14 2024-09-30 13F/A-2 DENALI THERAPEUTICS COM 24823R105 1,744,755 520,877 42.56 50,825 78.84 0.0037
2025-02-14 2024-09-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,744,755 520,877 50,825 0.0037
2024-11-14 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,744,755 520,877 50,825 0.0037
2025-05-14 2024-06-30 13F/A-2 DENALI THERAPEUTICS COM 24823R105 1,223,878 295,752 31.87 28,418 49.22 0.0022
2024-10-17 2024-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,223,878 295,752 28,418 0.0022
2024-08-14 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,223,878 295,752 28,418 0.0022
2024-10-17 2024-03-31 13F/A-2 DENALI THERAPEUTICS COM 24823R105 928,126 -49,367 -5.05 19,045 -9.21 0.0015
2024-08-16 2024-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 928,126 -49,367 19,045 0.0002
2024-05-15 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 928,126 -49,367 19,045 0.0015
2024-08-16 2023-12-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 977,493 -4,076 -0.42 20,977 3.59 0.0018
2024-02-13 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 977,493 -4,076 20,977 0.0018
2023-11-15 2023-09-30 13F DENALI THERAPEUTICS COM 24823R105 981,569 -95,317 -8.85 20,250 -36.28 0.0021
2023-08-14 2023-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,076,886 507,764 89.22 31,779 142.36 0.0031
2023-05-15 2023-03-31 13F DENALI THERAPEUTICS COM 24823R105 569,122 136,636 31.59 13,113 9.02 0.0014
2023-02-14 2022-12-31 13F DENALI THERAPEUTICS COM 24823R105 432,486 -248,846 -36.52 12,027 -42.48 0.0014
2022-11-14 2022-09-30 13F DENALI THERAPEUTICS COM 24823R105 681,332 258,321 61.07 20,909 67.96 0.0028
2022-10-27 2022-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 423,011 -282,644 -40.05 12,449 -45.16 0.0016
2022-08-15 2022-06-30 13F DENALI THERAPEUTICS COM 24823R105 423,011 -282,644 12,449 0.0016
2022-10-27 2022-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 705,655 418,397 145.65 22,702 77.19 0.0031
2022-05-13 2022-03-31 13F DENALI THERAPEUTICS COM 24823R105 705,655 418,397 22,702 0.0031
2022-02-14 2021-12-31 13F DENALI THERAPEUTICS COM 24823R105 287,258 -96,735 -25.19 12,812 -33.87 0.0016
2021-11-15 2021-09-30 13F DENALI THERAPEUTICS COM 24823R105 383,993 -47,039 -10.91 19,373 -42.70 0.0026
2021-08-23 2021-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 431,032 -31,128 -6.74 33,810 28.12 0.0045
2021-08-16 2021-06-30 13F DENALI THERAPEUTICS COM 24823R105 431,032 -31,128 33,810 0.0009
2021-05-17 2021-03-31 13F DENALI THERAPEUTICS COM 24823R105 462,160 242,732 110.62 26,389 43.59 0.0039
2021-02-16 2020-12-31 13F DENALI THERAPEUTICS COM 24823R105 219,428 -85,432 -28.02 18,378 68.25 0.0028
2020-11-13 2020-09-30 13F DENALI THERAPEUTICS COM 24823R105 304,860 -14,067 -4.41 10,923 41.65 0.0021
2020-08-14 2020-06-30 13F DENALI THERAPEUTICS COM 24823R105 318,927 163,505 105.20 7,711 183.28 0.0017
2020-05-26 2020-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 155,422 -93,387 -37.53 2,722 -37.21 0.0007
2020-05-15 2020-03-31 13F DENALI THERAPEUTICS COM 24823R105 155,422 -93,387 2,722 209.1063
2020-02-14 2019-12-31 13F DENALI THERAPEUTICS COM 24823R105 248,809 85,709 52.55 4,335 73.54 0.0010
2019-11-14 2019-09-30 13F DENALI THERAPEUTICS COM 24823R105 163,100 17,025 11.65 2,498 -17.61 0.0007
2019-08-14 2019-06-30 13F DENALI THERAPEUTICS COM 24823R105 146,075 14,183 10.75 3,032 -0.98 0.0008
2019-05-15 2019-03-31 13F DENALI THERAPEUTICS COM 24823R105 131,892 -72,322 -35.41 3,062 -27.42 0.0009
2019-02-14 2018-12-31 13F DENALI THERAPEUTICS COM 24823R105 204,214 17,312 9.26 4,219 3.84 0.0013
2019-04-23 2018-09-30 13F/A-2 DENALI THERAPEUTICS COM 24823R105 186,902 69,266 58.88 4,063 126.48 0.0010
2018-11-20 2018-09-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 186,902 0 4,063 0.0010
2018-11-14 2018-09-30 13F DENALI THERAPEUTICS COM 24823R105 186,902 69,266 4,063
2019-04-23 2018-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 117,636 35,427 43.09 1,794 10.81 0.0005
2018-08-14 2018-06-30 13F DENALI THERAPEUTICS COM 24823R105 117,636 35,427 1,794
2019-04-23 2018-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 82,209 80,547 4,846.39 1,619 5,896.30 0.0004
2018-05-14 2018-03-31 13F DENALI THERAPEUTICS COM 24823R105 82,209 80,547 1,619
2019-04-23 2017-12-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 1,662 1,662 27 0.0000
2018-02-14 2017-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,662 27 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.